# A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct05110846` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05110846](<https://clinicaltrials.gov/study/NCT05110846>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05110846

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT05110846. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-22 (actual); primary completion 2023-02-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT05110846, source copy `cardio:ctgov-nct05110846-2026-02-05`, retrieved 2026-10-26)
- Started: 2022-02-22 (actual) (ClinicalTrials.gov record NCT05110846, source copy `cardio:ctgov-nct05110846-2026-02-05`, retrieved 2026-10-26)
- Primary completion: 2023-02-28 (actual) (ClinicalTrials.gov record NCT05110846, source copy `cardio:ctgov-nct05110846-2026-02-05`, retrieved 2026-10-26)
- Completion: 2023-02-28 (actual) (ClinicalTrials.gov record NCT05110846, source copy `cardio:ctgov-nct05110846-2026-02-05`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT05110846, source copy `cardio:ctgov-nct05110846-2026-02-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05110846-2026-02-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- Condition: Obesity
- Condition: Overweight
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Placebo
- Intervention (Drug): CT-868
- Lead sponsor: Carmot Therapeutics, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Hoffmann-La Roche
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

## Provenance

Content hash: f84d9692d77ce802bff6a2597324d377b35b30feb9238e1f9d717e233c44ecf7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
